Consumers will have a new generic alternative to the widely used — and pricey — device to counter life-threatening allergic reactions.
Drugmaker Mylan is launching a generic version of its own EpiPen. The lower price could quiet criticism about the high cost of the brand-name anti-allergy drug. There's also a business twist.
The Auvi-Q epinephrine injector was pulled from the market in 2015 because of quality concerns. Now, the drug's maker says the problems have been solved and Auvi-Q will be available again in 2017.
Three former leaders of an influential task force that issues guidelines for preventive care says insurance coverage for highly rated tests and services shouldn't be mandatory.
In testimony prepared for a congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.
The company's lobbying of state legislatures is just one factor in EpiPen's dominance of the market. Manufacturers of competing devices have struggled to gain a foothold.
Four years after user fees were imposed to speed up the review of generic drug applications by the Food and Drug Administration, more than 4,000 generics remain in limbo.
Mylan's move comes amid pressure from consumers and Congress to lower the allergy drug's price. In less than 10 years, the price has risen from about $100 to more than $600 for an injector two-pack.